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Abstract
Antivascular therapy has emerged as a rational strategy to improve the treatment of androgen-independent
prostate cancer owing to the necessity of establishing a vascular network for the growth and progression of
the primary and metastatic tumor. We determined whether recombinant human apolipoprotein(a) kringle V, rhLK8,
produces therapeutic efficacy in an orthotopic human prostate cancer animal model. Fifty thousand androgen-
independent human prostate cancer cells (PC-3MM2) were injected into the prostate of nude mice. After 3 days,
these mice were randomized to receive the vehicle solution (intraperitoneally [i.p.], daily), paclitaxel (8 mg/kg i.p.,
weekly), rhLK8 (50 mg/kg i.p., daily), or a combination of paclitaxel and rhLK8 for 4 weeks. Treatment with pacli-
taxel or rhLK8 alone did not show significant therapeutic effects on tumor incidence or on tumor size compared
with the control group. The combination of rhLK8 and paclitaxel significantly reduced tumor size and incidence of
lymph node metastasis. Significant reduction in microvessel density and cellular proliferation and induction of
apoptosis of tumor cells, and tumor-associated endothelial cells, were also achieved. Similarly, PC-3MM2 tumors
growing in the tibia showed significant suppression of tumor growth and lymph node metastasis by the combi-
nation treatment with rhLK8 and paclitaxel. The integrity of the bone was significantly preserved, and apoptosis of
tumor cells and tumor-associated endothelial cells was increased. In conclusion, these results suggest that target-
ing the tumor microenvironment with the antivascular effect of rhLK8 combined with conventional cytotoxic che-
motherapy could be a new and effective approach in the treatment of androgen-independent prostate cancer and
their metastases.
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Introduction
Prostate cancer is the most commonly diagnosed cancer among men
in the Western world. The lifetime risk of having microscopic evidence
of prostate cancer for a 50-year-old man is 40%. Prostate cancer is a
complex disease, and it displays extensive heterogeneity both genetically
and morphologically [1–3]. Although prostate cancer screening using
serum prostate-specific antigen has led to increased detection of early-
stage prostate cancer at diagnosis, many (∼24%) patients have clinical
or subclinical metastatic disease, which cause devastating symptoms
and require systemic therapies such as hormone ablation. However, de-
spite an initial favorable response to the therapy [4], heterogeneity and
genetic instability of tumor cells lead to the development of androgen
independence; then, taxane-based chemotherapy can prolong the
median survival of the patients for only limited time owing to the emer-
gence of a multidrug-resistant clonal population. Therefore, the de-
velopment of a new treatment modality for androgen-independent
prostate cancer is urgently required to overcome multidrug resistance.
To overcome extreme heterogeneity and genetic instability of tumor
cells, targeting relatively more homogeneous and genetically stable host
organ microenvironment is an emerging and popular concept.
Tumor growth and metastasis require the establishment of a new
vascular network, a process known as angiogenesis, to supply nutrients
and oxygen and to drain waste products from the tumor mass [5–7].
Therefore, antiangiogenic therapy that can starve the tumors has been
regarded as an attractive approach to treat cancer. Currently, many of
these antiangiogenic molecules are under clinical investigation as anti-
cancer drugs and most of them have shown promising anticancer effi-
cacy in preclinical settings [8,9].
Kringle is a protein structural motif that consists of approximately
80 amino acids with conserved rigid triple disulfide bonds [10]. Kringle
domains are present in several proteins with functions of a growth
factor, functions in blood coagulation, and functions in fibrinolysis
(hepatocyte growth factor, prothrombin, plasminogen, urokinase, etc)
and have been identified as angiogenesis inhibitors both in vitro and
in vivo [11]. Human apolipoprotein(a) [apo(a)] contains multiple re-
peats homologous to plasminogen kringle IV, followed by a single copy
of a homolog of plasminogen kringle V and an inactive copy of the
protease domain (Figure 1) [12], and is a glycoprotein component of
lipoprotein(a) particles [13–16]. We have demonstrated that a recom-
binant peptide named LK68, a fragment of human apo(a) consisting of
KIV9, KIV10, and KV, inhibits angiogenesis in vitro, in part by abro-
gating the activation of extracellular signal–regulated kinases 1 and 2 in
endothelial cells through a protein tyrosine phosphatase–dependent
mechanism [17,18]. Surprisingly, recombinant human apo(a) kringle V,
termed rhLK8, displayed an antiangiogenic activity almost equivalent
to that observed for LK68. It inhibited the migration of endothelial
cells in vitro and new capillary formation in vivo, in part by the down-
regulation of the activation of focal adhesion kinase and the inhibition
of consequent formation of actin stress fibers and focal adhesions [19].
In preclinical animal models, systemic administration of LK68 pro-
teins, retroviral gene transfer with LK68, or adenoassociated virus–
mediated gene expression of LK68 suppress the growth and metastasis
of human colorectal carcinoma, lung carcinoma, or hepatocellular
carcinoma [17,20–22]. However, most of these studies have been per-
formed by using ectopic animal models wherein tumor cells were im-
planted subcutaneously, lacking the essential cross talk between cancer
cells and the organ-specific host microenvironment [23–26]. Therefore,
it is necessary to evaluate the antiangiogenic and antitumor effects of a
certain drug such as rhLK8 using an orthotopically implanted tumor
models that can reflect the physiologically relevant interaction of cancer
cells and the host microenvironment.
In this study, we evaluated the therapeutic effects of the recombi-
nant human apo(a) kringle V, rhLK8, alone and in combination with
paclitaxel against androgen-independent human prostate cancer cells
growing orthotopically in nude mice. We demonstrate that the treat-
ment produced apoptosis of tumor-associated endothelial cells and
surrounding tumor cells, leading to a significant suppression of pri-
mary tumor growth and their metastasis.
Materials and Methods
Cells and Cell Culture Methods
Androgen-independent human prostate cancer cells PC-3MM2
were maintained as monolayer cultures in minimum essential medium
(Life Technologies, Grand Island, NY) supplemented with 10% fetal
bovine serum, sodium pyruvate (110 μg/ml), nonessential amino acids
(glycine at 7.5 mg/L, L-alanine at 8.9 mg/L, L-asparagine at 13.2 mg/L,
L-aspartic acid at 13.3 mg/L, L-glutamic acid at 14.7 mg/L, L-proline
at 11.5 mg/L, and L-serine at 10.5 mg/L), 4 mM L-glutamine, a two-
fold concentrated vitamin solution (Life Technologies), and penicillin
(100 IU/ml)–streptomycin (100 μg/ml; Flow Laboratories, Rockville,
MD) in an atmosphere of 5% CO2 and 95% air at 37°C.
rhLK8 and Paclitaxel
Saccharomyces cerevisiae BJ3501 strain was transformed by an ex-
pression vector for rhLK8, which was constructed to express rhLK8
as a fusion protein to an α factor signal sequence under the control of
yeast Gal1 promoter and subsequently processed to be secreted into the
culture medium [27]. rhLK8 proteins were purified to homogeneity
from the culture supernatant of S. cerevisiae BJ3501 expressing rhLK8
as previously described [28]. Purified rhLK8 proteins were stored in the
buffer containing 100 mM NaCl and 150 mM L-glycine (pH 4.2).
Paclitaxel (Taxol; Bristol-Myers Squibb C., Princeton, NJ) was diluted
in distilled water at 1 mg/ml for intraperitoneal (i.p.) injection.
Animals
Male athymic nude mice (NCI-nu) were purchased from the
Animal Production Area of the National Cancer Institute – Frederick
Cancer Research Facility. The mice were housed and maintained in
specific pathogen-free conditions in facilities approved by the American
Association for Accreditation of Laboratory Animal Care, which met
all current regulations and standards of the US Department of Health
and Human Services and the National Institutes of Health. The mice
were used in accordance with institutional guidelines when they were
6 to 8 weeks old.
Establishment of Orthotopic Primary and Bone Prostate
Cancer Animal Models in Nude Mice
PC-3MM2 cells were harvested from subconfluent cultures by
brief exposure to 0.25% trypsin and 0.02% EDTA. Trypsinization
was stopped with medium containing 10% fetal bovine serum, and
the cells were washed with serum-free medium and resuspended in
Ca2+/Mg2+–free Hank’s balanced salt solution. Only suspensions
consisting of single cells with more than 90% viability were used.
Mice were anesthetized by i.p. injection of 0.5 mg/kg body weight
Nembutal (Abbott Laboratories, North Chicago, IL). PC-3MM2
cells were injected into the prostate at a concentration of 5 × 104 cells
in 50 μl as described previously [29]. Briefly, a lower midline incision
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was created, and the prostate was exposed. A tumor cell suspension
was injected the dorsal prostatic lobes using a 30-gauge needle. The
abdominal wound was closed in one layer with wound clips (Auto-
clip; Clay Adams, Parsippany, NJ). To produce bone tumors, we first
harvested PC-3MM2 cells as described, and before intratibial injec-
tion, the mice were anesthetized with Nembutal (0.5 mg/kg body
weight). A percutaneous intraosseal injection was made by drilling
a 27-gauge needle into the tibia immediately proximal to the tuber-
ositas tibiae. After penetration of the cortical bone, the needle was
further inserted into the shaft of the tibia and was used to deposit
20 μl of the tumor cell suspension (2 × 105 cells) in the cortex with
the use of a calibrated, push button–controlled dispensing device
(Hamilton Syringe Co, Reno, NV). To prevent leakage of cell
suspensions, a cotton swab was held against the injection site for
1 minute [30,31]. The procedure was well tolerated, and there were
no anesthesia-related deaths.
Therapy
In the first set of experiment, we determined the biologic optimal
dose of rhLK8. Mice were injected with 5 × 104 cells of PC-3MM2
into the prostate and waited for 2 weeks to allow the tumors to de-
velop the vascular networks essential for the tumor growth. Mice
were then treated by daily i.p. injection of rhLK8 at doses of 12.5,
25, or 50 mg/kg alone or in combination with weekly i.p. injection
of 8 mg/kg paclitaxel. Mice underwent necropsy 4 weeks later, and
immunohistochemistry (IHC) was performed. Biologic activity of
rhLK8 alone or in combination with paclitaxel was evaluated by
detecting apoptosis of tumor-associated endothelial cells and sur-
rounding tumor cells.
The second set of experiment was performed to determine the
therapeutic efficacy of rhLK8 with or without paclitaxel. Three days
after intraprostatic injection of cells, the mice were randomized into
four groups and treated as follows: (1) daily i.p. administration of
vehicle (100 mM NaCl, 150 mM L-glycine, pH 4.2), (2) i.p. injec-
tion of paclitaxel (8 mg/kg) once per week and daily i.p. injection of
vehicle, (3) daily i.p. injection of rhLK8 (50 mg/kg), and (4) daily i.p.
administration of rhLK8 (50 mg/kg) and i.p. injection of paclitaxel
(8 mg/kg) once per week. Two weeks after intratibial injection, the
mice were randomized into four groups and then treated as described
previously. After 4 weeks of treatment, the mice were killed by CO2
inhalation. Body weight, tumor incidence, tumor weight, and inci-
dence of regional lymph node metastasis were recorded. Tumors
and regional lymph nodes were processed for histologic and immuno-
histochemical analysis.
Digital Radiography
After 4 weeks of treatment, mice with bone tumors were anesthe-
tized with Nembutal (0.5 mg/kg body weight) and placed in a prone
position. Digital radiography of both hind limbs was carried out using
the Faxitron MX-20 X-ray machine (Faxitron X-ray Corp, Wheeling,
IL). Both tumor-bearing and tumor-free, uninjected control legs of
each mouse were resected. Tumor weight was calculated by subtracting
the weight of tumor-free leg from that of tumor-bearing leg.
Preparation of Tissues
Prostate tumor tissues or bone tumor tissues including the tibia
and surrounding muscles were fixed in 10% buffered formalin and
embedded in paraffin for sectioning. For frozen blocks, prostate tumor
tissues were embedded immediately in ornithine carbamyl transferase
compound (Miles, Elkhart, IN), snap frozen in liquid nitrogen, and
stored at −70°C. Bone tumor tissues were fixed in 4% paraformalde-
hyde containing 0.075M lysine and 0.01M sodium periodate solution
and embedded in ornithine carbamyl transferase compound for frozen
sectioning. Fixed bone tissues were decalcified and processed as previ-
ously described [32]. All macroscopically enlarged regional lymph
nodes were harvested, and the presence of metastatic disease was con-
firmed by hematoxylin and eosin staining.
Immunohistochemical Analyses
Paraffin embedded tissues were sectioned (4-6 μm thick) and stained
for hematoxylin and eosin and proliferating cell nuclear antigen
(PCNA). Frozen tissues used for CD31/platelet endothelial cell ad-
hesion molecule 1 (PECAM-1) and/or deoxynucleotidyl transferase-
mediated nick end labeling (TUNEL) staining were prepared and
fixed in cold acetone. TUNEL assay was performed with a commer-
cially available apoptosis detection kit (Promega Corp, Madison, WI)
with modification. IHC procedures were performed, and all antibodies
and agents for IHC were purchased from sources exactly as described
previously [33]. Control samples exposed to secondary antibody alone
showed no specific staining. Stained sections were examined under an
Olympus BX51 microscope (Olympus, Center Valley, PA) equipped
with Olympus DP71 12.5-megapixel digital microscope camera.
Immunofluorescent Double Staining for CD31/PECAM-1
(Endothelial Cells) and TUNEL
TUNEL assay was performed after CD31/PECAM-1 immuno-
fluorescent staining as described previously [33]. For quantification
of endothelial cells, the samples were incubated with 1 μg/ml of
Hoechst 33342 stain for 1 minute at room temperature. Propyl gallate
was placed on each slide and then covered with a glass coverslip (Fischer
Figure 1. Schematic representation of apo(a), which contains 10 unique kringle 4-like domains (designated IV-1 through IV-10; kringle IV-2 is
variably repeated), one kringle 5-like domain (KV; gray circle), and a protease domain. An 86-amino-acid sequence of the rhLK8 was shown
with the cysteine residues conserved in the kringle domain underlined.
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Scientific, Fair Lawn, NJ). Endothelial cells were stained for red fluo-
rescence, whereas DNA fragmentation (TUNEL assay) was stained for
green fluorescence. Colocalization of red and green signals produced
yellow signals (apoptotic endothelial cells).
Quantification of TUNEL, PCNA, and Mean Vessel Density
Quantification of apoptotic endothelial cells was expressed as an
average of the ratio of the apoptotic endothelial cells to the total
number of endothelial cells in 5 to 10 random 0.011-mm2 fields at
400× magnification. For the quantification of total TUNEL-positive
cells, the apoptotic cells were counted in 10 random 0.159-mm2 fields at
100× magnification. To quantify PCNA-positive cells and mean vessel
density (MVD), 10 to 12 random 0.159-mm2 fields in the prostate
at 100× magnification were captured for each tumor. MVD was deter-
mined according to themethod described previously [33]. CD31-positive
tumor vasculature was also visualized using 3,3′-diaminobenzidine
(DAB) as a substrate of the horseradish peroxidase–conjugated sec-
ondary antibody. Vessel area was then determined by counting the pixel
in each field using analySIS FIVE image analysis software (Olympus
Soft Imaging Solutions GmbH,Münster, Germany).
Statistical Analysis
The χ2 test was used to determine the significance of differences in
tumor incidence and incidence of lymph node metastasis. Differences
in tumor weight of mice were compared with Mann-Whitney U test.
The unpaired Student’s t test was used to evaluate the differences in
PCNA-positive cells, MVD (CD31/PECAM-1), number of apoptotic
cells (TUNEL), and percentage of apoptotic endothelial cells.
Results
In the first set of experiment, intermittent apoptosis of tumor-associated
endothelial cells and tumor cells fed by these vessels was observed with a
single treatment with paclitaxel and more so with 25 or 50 mg/kg
rhLK8 alone. However, the induction of apoptosis was significantly
increased with the combined treatment of rhLK8 with paclitaxel in
a dose-dependent manner (data not shown) without detectable local
or systemic toxicities. On the basis of these results, the optimal biologic
dose of rhLK8 was determined to be 50 mg/kg.
In the next set of experiments, we determined the therapeutic
effects of rhLK8 administered alone or in combination with paclitaxel
against PC-3MM2 cells growing orthotopically in the prostate of
nude mice. Results of the two independent experiments were similar
and therefore combined for analysis (Table 1). All the control mice
(15/15) developed large prostate tumors (median weight = 2.3 g,
range = 0.4-3.6 g) and had histologically confirmed metastasis to
the regional lymph nodes. In the paclitaxel-treated group, all 19 mice
had prostate tumors (median weight = 2.0 g, range = 0.4-3.8 g) and
also had lymph node metastasis. All mice administered with rhLK8
(17/17) had prostate tumors (median weight = 1.8 g, range = 0.1-3.1 g),
and 12 of 17 mice had lymph node metastasis. Mice treated with the
combination of rhLK8 and paclitaxel showed significantly decreased
tumor weight (median weight = 0.6 g, range = 0-2.6 g, P < .01, com-
pared with the control group) and lymph node metastasis (10/18, P < .01,
compared with the control group). Tumor incidence was also decreased
but not statistically significant.
Cell Proliferation and Apoptosis
IHC analyses were carried out at the peripheral zones of the
tumors to avoid zones of central necrosis. We determined whether the
decrease in tumor weight and lymph node metastasis in mice treated
with rhLK8 alone or in combination with paclitaxel was due to the
inhibition of tumor cell proliferation, the induction of tumor cell
apoptosis, or both. The number of PCNA-positive and TUNEL-positive
cells in PC-3MM2 tumors was counted (Figure 2 and Table 2). The
mean number of PCNA-positive tumor cells in tumors from control
mice was 197.8 ± 15.5. Administration of rhLK8 did not significantly
decrease the number of proliferating cells (187.1 ± 10.3, P > .05). How-
ever, tumors from mice treated with paclitaxel or paclitaxel plus rhLK8
showed a significant decrease in the number of PCNA-positive cells
(151.4 ± 11.2 and 150.5 ± 14.4, respectively, P < .005). The mean
number of TUNEL-positive tumor cells in tumors from control mice
and mice treated with paclitaxel had similar levels of apoptosis (5.2 ±
4.8 and 3.9 ± 5.9, respectively, P > .05). Administration of rhLK8
slightly increased the number of apoptotic tumor cells, but there was
no statistical significance (11.4 ± 13.3, P > .05). However, in mice
treated with rhLK8 in combination with paclitaxel, there was a
significant increase in the number of TUNEL-positive tumor cells
(29.5 ± 13.4, P < .01).
Microvessel Density
Next, we determined whether the increase in apoptosis of tumor
cells correlated with a suppression of vascularization. Samples were
stained for CD31/PECAM-1 to determine MVD. In control tumors,
the MVD was 32.7 ± 9.3. Treatment with paclitaxel or rhLK8 did not
decrease the MVD (36.3 ± 15.2 and 28.8 ± 12.8, respectively, P > .05),
whereas treatment with rhLK8 in combination with paclitaxel pro-
duced a significant decrease in MVD (16.9 ± 10.4, P < .01; Table 2).
We also determined the vessel area by counting the pixels generated by
CD31-positive tumor vasculature. Consistent with the result of MVD
analysis, the relative vessel area in tumors from control mice (3.7 ± 1.2)
was similar to that observed in tumors from mice treated with paclitaxel
or rhLK8 (4.0 ± 1.5 and 3.4 ± 2.3, respectively, P > .05), whereas treat-
ment with rhLK8 plus paclitaxel decreased significantly the relative
vessel area (1.8 ± 0.8, P < .01; Figure 2).
Immunofluorescent Double Staining for Endothelial Cells
(CD31/PECAM-1) and TUNEL
We also determined whether the treatment with paclitaxel, rhLK8,
or rhLK8 plus paclitaxel can induce the apoptosis of tumor-associated
endothelial cells. The immunofluorescent double staining for CD31
(red ) and TUNEL (green) and subsequent colocalization technique
allowed detection of apoptotic tumor cells (green) and apoptotic tumor-
associated endothelial cells (yellow; Figure 3 and Table 2). In the control
group and the paclitaxel-treated group, the median ratio of apoptotic
Table 1. Treatment of PC-3MM2 Implanted into the Prostate of Male Nude Mice with rhLK8
and Paclitaxel.
Treatment
Groups
Incidence
of Tumor
Tumor Weight (g),
Median (Range)
Incidence of
L/N Metastasis
Vehicle 15/15 2.3 (0.4-3.6) 15/15
Paclitaxel 19/19 2.0 (0.4-3.8) 19/19
rhLK8 17/17 1.8 (0.1-3.1) 12/17
rhLK8 + paclitaxel 15/18 0.6 (0-2.6)* 10/18*
A total of 5 × 104 PC-3MM2 cells were implanted into the prostate of nude mice. Three days later,
treatment with vehicle, paclitaxel (8 mg/kg, weekly i.p. injection), or rhLK8 (50 mg/kg, daily i.p.
injection), alone or in combination with paclitaxel, was started and continued for 4 weeks.
*P < .01.
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endothelial cells was 0% (range = 0-5% and 0-7%, respectively). Treat-
ment with rhLK8 significantly increased the ratio of apoptotic endo-
thelial cells (median = 6%, range = 0%-14%, P < .005) and more so
with the combination of rhLK8 and paclitaxel (median = 23%, range =
0%-29%, P < .01). The differences in the ratio of apoptotic endothelial
cells between tumors from mice treated with rhLK8 and mice treated
with rhLK8 plus paclitaxel were also significant (P < .05).
Therapy for Nude Mice Bearing PC-3MM2 Tumors
in the Tibia
We determined whether the biologic activity of rhLK8 observed in
prostate tumors growing in the prostate of nude mice can be extrap-
olated to the prostate tumors growing in the tibia of nude mice. We
injected the PC-3MM2 human prostate carcinoma cells into the tibia
of nude mice and waited for 2 weeks to allow the tumors to develop
Figure 2. Analysis of cell proliferation, apoptosis, and MVD. Prostate tumor specimens from different treatment groups underwent
immunohistochemical analysis for the expression of CD31 (MVD), PCNA (cell proliferation), and apoptosis (TUNEL). Treatment of PC-
3MM2 human prostate cancer in nude mice with rhLK8 plus paclitaxel significantly decreased MVD and tumor cell proliferation and
increased apoptotic tumor cells.
Table 2. Response to Treatment of Human Prostate Carcinoma (PC-3MM2) Growing in the
Prostate of Nude Mice.
Treatment Groups* Tumor Cells Endothelial Cells
PCNA+† TUNEL+† CD31+† CD31/TUNEL+‡ (%)
Vehicle 197.8 ± 15.5 5.2 ± 4.8 32.7 ± 9.3 0 (0-5)
Paclitaxel 151.4 ± 11.2§ 3.9 ± 5.9 36.3 ± 15.2 0 (0-7)
rhLK8 187.1 ± 10.3 11.4 ± 13.3 28.8 ± 12.8 6 (0-14)§
rhLK8 + paclitaxel 150.5 ± 14.4§ 29.5 ± 13.4¶ 16.9 ± 10.4¶ 23 (0-29)¶
*A total of 5 × 104 PC-3MM2 cells were implanted into the prostate of nude mice. Three days
later, treatment with vehicle, paclitaxel (8 mg/kg, weekly i.p. injection), or rhLK8 (50 mg/kg, daily
i.p. injection), alone or in combination with paclitaxel, was started and continued for 4 weeks.
†Mean ± SD.
‡Ratio of the median number of apoptotic endothelial cells to the total number of endothelial cells
in 7 to 10 random 0.159-mm2 fields.
§P < .005.
¶P < .01.
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vascular networks essential for the tumor growth. Then we treated
mice with rhLK8 alone or in combination with paclitaxel for 4 weeks.
All mice had tumors in their legs and also had regional lymph node
metastasis. Mice from the control group had large tumors in the
tibia and surrounding muscles (median = 1.2 g, range = 0.5-2.0 g).
Median tumor sizes of mice treated with paclitaxel or rhLK8 were
0.8 g (range = 0.8-1.5 and 0.2-4.3 g, respectively, P > .05, compared
with the control group). However, treatment with rhLK8 in combi-
nation with paclitaxel produced a significant therapeutic efficacy on
tumor size (median = 0.6 g, range = 0.2-1.4 g, P < .05, compared with
the control group) (Table 3).
As shown in Figure 4A, digital radiography of the hind legs revealed
severe destruction of bone in the control group of mice or in the mice
treated with paclitaxel. Osteolytic bone lesions were less severe with
the treatment with rhLK8 and were the least severe with the combi-
nation treatment with rhLK8 and paclitaxel. In mice treated with
rhLK8 and paclitaxel, bone integrity was well preserved.
We also determined whether the results produced by the treat-
ment with rhLK8 in combination with paclitaxel resulted from the
induction of apoptosis in tumor-associated endothelial cells and the
surrounding tumor cells. Tumor specimens were stained for CD31/
PECAM-1 (red) and TUNEL (green) to detect apoptotic (TUNEL
positive) tumor cells (green) and apoptotic endothelial cells (yellow).
Tumor specimens from control mice or from mice treated with
paclitaxel showed little apoptotic tumor cells and tumor-associated
endothelial cells. However, treatment with rhLK8 induced apoptosis of
tumor cells and tumor-associated endothelial cells, and this induction
of apoptosis was significantly increased with the combined treatment
with rhLK8 and paclitaxel (Figure 4B).
Discussion
The standard therapy for men with hormone-refractory prostate
cancer is taxane-based chemotherapy. However, responses are not
durable, and progression of disease is frequent. Therefore, there is an
unmet medical need for the alternative therapeutic approaches that
can improve the prognosis of patients.
Tumor-Associated Endothelial Cells
It has been reported that the blood vessels in the tumors are irreg-
ular, tortuous, and leaky than those of normal blood vessels [7,34].
Endothelial cells in the human tumors are highly proliferative than
those in their corresponding normal tissues. Although prostate carci-
noma has a relatively low endothelial cell proliferative index, endo-
thelial cell turnover in the prostate carcinoma (mean ± SD = 2.0% ±
1.4%; median = 1.9%) is ∼20-fold higher than the proliferative cell
index of the endothelial cells (around 0.1%) in the normal tissues [35].
Given the findings that antiangiogenic agents may target the proliferat-
ing endothelial cells but not the dormant endothelial cells, this selec-
tivity should lead to the minimal adverse effects even after prolonged
treatment. Furthermore, targeting of endothelial cells may have a self-
amplification mechanism in that the induction of apoptosis in endo-
thelial cells may lead to the apoptosis in ∼70-fold more tumor cells
dependent on those endothelial cells, as assessed by the findings that
Figure 3. Double immunofluorescence staining of prostate tumor specimens for CD31/PECAM-1 (red) and TUNEL (green). Note the
significant increase of apoptosis of tumor-associated endothelial cells as well as adjacent tumor cells in the prostate tumors treated
with rhLK8 plus paclitaxel.
Table 3. Treatment of PC-3MM2 Implanted into the Tibia of Male Nude Mice with rhLK8
and Paclitaxel.
Treatment
Groups
Incidence
of Tumor
Tumor Weight (g),
Median (Range)
Incidence of
L/N Metastasis
Vehicle 10/10 1.2 (0.5-2.0) 10/10
Paclitaxel 8/8 0.8 (0.5-1.8) 8/8
rhLK8 8/8 0.8 (0.2-4.3) 8/8
rhLK8 + paclitaxel 10/10 0.6 (0.2-1.4)* 10/10
A total of 2 × 105 PC-3MM2 cells were implanted into the tibia of nude mice. Two weeks later,
treatment with vehicle, paclitaxel (8 mg/kg, weekly i.p. injection), or rhLK8 (50 mg/kg, daily i.p.
injection), alone or in combination with paclitaxel, was started and continued for 4 weeks.
*P < .05.
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an index of overall ratio of proliferating tumor cells to the proliferating
endothelial cells in the human prostate carcinoma has been determined
to be between 40 and 70 [35]. Microvessel density has been considered
as a negative prognostic indicator for prostate cancer [36], with a signif-
icant correlation among Gleason score, pathologic stage, tumor metas-
tasis, and patient survival [37,38]. Therefore, targeting angiogenesis has
been regarded as a promising new treatment for prostate cancer, and
this has been supported by several clinical trials of the docetaxel-based
combination with angiogenesis inhibitors [39].
Therapeutic Efficacy
In the present study, treatment with paclitaxel alone significantly
decreased the proliferation index of tumor cells but did not affect
tumor-associated endothelial cells. Nevertheless, treatment with
rhLK8 alone induced the apoptosis of endothelial cells but did not
affect the proliferation of tumor cells. Significantly, combined treat-
ment with rhLK8 and paclitaxel decreased cellular proliferation index
with a significant induction of apoptosis of endothelial cells of tumor-
associated vasculature, which implicated a potential synergistic thera-
peutic effect of rhLK8 combined with paclitaxel. Moreover, induction
of apoptosis of tumor cells was also significantly increased, suggesting
that apoptosis of endothelial cells may lead to the disruption of tumor
vasculature followed by necrosis of surrounding tumors. As previously
reported, antiangiogenic therapy is often not cytocidal but cytostatic
in nature; the treatment outcome of antiangiogenic drugs as a single
agent is relatively limited but a combination of antiangiogenic drugs
with conventional chemotherapy may enhance treatment outcomes
[40,41], although the underlying mechanism of this synergism is
not yet clear. A potential explanation can be referred to the inherent
leakiness of the tumor vasculature and, hence, the impairment of drug
delivery to cancer cells that is caused by a high interstitial pressure;
antiangiogenic therapy might initially make blood flow more efficient,
resulting in improved tissue oxygenation and increased delivery of
cytotoxic agents [42–44].
Apolipoprotein(a)
Plasminogen kringle 5 (PK5), which showed a significant sequence
identity with apo(a) kringle V, has the most potent antiangiogenic
activities to inhibit the growth of a variety of tumors in animal models
with the significantly decreased mean microvessel density [45–50]. It
inhibits the proliferation, migration, and tube formation of endothelial
cells in vitro [51,52] and induces cell cycle arrest [53], autophagy [54],
and apoptosis of proliferating endothelial cells [55]. PK5 interacts with
a chaperone protein associated with stress in endoplasmic reticulum,
the glucose-regulated protein 78 (GRP78), on the cell surface of the
proliferating endothelial cells [55]. GRP78–caspase 7 complex is be-
lieved to prevent the cells from apoptotic cell death. Binding of PK5
with GRP78 may cause the dissociation of this complex, subsequent
release, and activation of caspase 7, leading to the apoptotic cell death.
Taken together with the findings that PK5 treatment promotes mito-
chondrial depolarization, followed by the release of cytochrome c and
activation of caspase cascades including caspase 3, 6, and 7 [50], PK5
seems to induce the apoptosis in endothelial cells through the intrinsic
pathway. Binding of PK5 to another cell surface target, the voltage-
dependent anion channel, and induction of apoptosis through this
interaction have also been reported [56]. These studies have also shown
Figure 4. Digital radiography and immunofluorescent double labeling of tumors derived from human prostate cancer cells growing in the
tibia of nude mice for CD31/PECAM-1 and TUNEL. (A) Digital radiography of the hind legs revealed destruction of bone in control mice or
in mice treated with paclitaxel. Mice treated rhLK8 alone had diminished bone lysis, and the combination of rhLK8 with paclitaxel was
associated with preservation of the bone structure, in a dose-dependent manner. (B) Tumor specimens from control mice or mice treated
with paclitaxel showed little apoptotic tumor cells and tumor-associated endothelial cells. However, treatment with rhLK8 induced
apoptosis of tumor cells and tumor-associated endothelial cells, and this induction of apoptosis was significantly increased with the
combined treatment with rhLK8 and paclitaxel.
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that PK5 can induce the apoptosis of tumor cells under stress, such as
hypoxia, in addition to the endothelial cells. Although we have clearly
demonstrated the induction of apoptosis mediated by rhLK8 in endo-
thelial cells of the tumor-associated vasculature in this study, its direct
effect on endothelial cell in vitro is moderate and much remains to be
elucidated. Unlike PK5, rhLK8 did not induce the apoptosis of any
tumor cells tested in vitro. However, under a limited condition such
as nutrient deprivation, treatment with rhLK8 showed induction of
endothelial cell apoptosis in vitro. Moreover, our preliminary data
showed that rhLK8 may induce apoptosis of endothelial cells in vitro
through binding with the GRP78 protein on the endothelial cell sur-
face. No rhLK8-mediated activation of caspase 3 was observed in en-
dothelial cells, when the expression of GRP78 had been knocked down
by the transduction of GRP78 siRNA (J.H. Ahn et al., unpublished
data). However, this does not rule out the possibility that rhLK8
may affect the interaction of tumor-associated vasculatures with tumor
cells or other cells such as immune cells in vivo because PK5 can exert
its antitumor activity either by inhibiting the recruitment of tumor-
associated macrophages or by promoting the recruitment of neutrophils
or NKT lymphocytes [45,47]. The potential direct effects of rhLK8 on
the growth of tumors remain largely to be elucidated, although LK8
gene expression in the hepatocellular carcinoma cells inhibited primary
tumor growth and prolonged survival [22].
We have demonstrated here that administration of rhLK8 in
combination with paclitaxel can produce a significant therapy against
androgen-independent human prostate carcinoma cells growing
orthotopically in the prostate of nude mice. Moreover, the combina-
tion therapy for rhLK8 with paclitaxel significantly inhibited the
growth of prostate tumor cells in the tibial bone of nude mice, leav-
ing bone integrity of these mice well preserved.
In conclusion, these results suggest that targeting the tumor micro-
environment with the antivascular activity of rhLK8 combined with
conventional cytotoxic chemotherapy could be a new and effective
approach in the treatment of androgen-independent prostate cancer
and their metastases.
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